Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600351.SS Stock Summary
In the News
600351.SS Financial details
Company Rating
Buy
Market Cap
4.76B
Income
211.08M
Revenue
2.94B
Book val./share
4.02
Cash/share
0.78
Dividend
0.05
Dividend %
0.75%
Employees
4.37K
Optionable
No
Shortable
Yes
Earnings
26 Apr 2024
P/E
23.97
Forward P/E
-
PEG
16.21
P/S
1.8
P/B
1.66
P/C
7.77
P/FCF
21.57
Quick Ratio
1.67
Current Ratio
2.18
Debt / Equity
0.08
LT Debt / Equity
0
-
-
EPS (TTM)
0.28
EPS next Y
-
EPS next Q
-
EPS this Y
-41.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-16.74%
Revenue last 5Y
-1.41%
Revenue Q/Q
-8.98%
EPS Q/Q
-23.13%
-
-
-
-
SMA20
-
SMA50
-14.29%
SMA100
-25%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
7%
ROC
0.08%
Gross Margin
56%
Oper. Margin
8%
Profit Margin
7%
Payout
26%
Shs Outstand
760M
Shs Float
574.29M
-
-
-
-
Target Price
-
52W Range
4.94-9.0
52W High
-32.67%
52W Low
+51.5%
RSI
43
Rel Volume
1.21
Avg Volume
22.09M
Volume
26.64M
Perf Week
-3.96%
Perf Month
-0.98%
Perf Quarter
-
Perf Half Y
-28.62%
-
-
-
-
Beta
0.277
-
-
Volatility
0.12%, 0.1%
Prev Close
0.66%
Price
6.06
Change
-1.3%
600351.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.72 | 4.37 | 3.39 | 3.59 | 3.64 | |
Net income per share | 0.35 | 0.02 | 0.14 | 0.24 | 0.14 | |
Operating cash flow per share | 0.54 | 0.61 | 0.5 | 0.57 | 0.62 | |
Free cash flow per share | 0.46 | 0.39 | 0.41 | 0.44 | 0.53 | |
Cash per share | 1.03 | 0.62 | 0.46 | 0.56 | 0.84 | |
Book value per share | 3.69 | 3.87 | 3.62 | 3.8 | 3.97 | |
Tangible book value per share | 3.13 | 3.44 | 3.21 | 3.36 | 3.54 | |
Share holders equity per share | 3.69 | 3.87 | 3.62 | 3.8 | 3.97 | |
Interest debt per share | 1.37 | 1.39 | 0.89 | 0.73 | 0.62 | |
Market cap | 4.36B | 4.05B | 3.82B | 6.99B | 4.4B | |
Enterprise value | 4.61B | 4.49B | 4.12B | 7.05B | 4.17B | |
P/E ratio | 15.96 | 375.41 | 35.57 | 37.37 | 42 | |
Price to sales ratio | 1.5 | 1.33 | 1.47 | 2.53 | 1.62 | |
POCF ratio | 10.23 | 9.53 | 10.03 | 15.98 | 9.55 | |
PFCF ratio | 12.17 | 15.12 | 12.01 | 20.42 | 11.04 | |
P/B Ratio | 1.51 | 1.51 | 1.37 | 2.39 | 1.48 | |
PTB ratio | 1.51 | 1.51 | 1.37 | 2.39 | 1.48 | |
EV to sales | 1.58 | 1.48 | 1.58 | 2.55 | 1.53 | |
Enterprise value over EBITDA | 8.37 | 8.14 | 12.19 | 16.95 | 10.85 | |
EV to operating cash flow | 10.82 | 10.56 | 10.81 | 16.12 | 9.05 | |
EV to free cash flow | 12.87 | 16.74 | 12.94 | 20.6 | 10.47 | |
Earnings yield | 0.06 | 0 | 0.03 | 0.03 | 0.02 | |
Free cash flow yield | 0.08 | 0.07 | 0.08 | 0.05 | 0.09 | |
Debt to equity | 0.36 | 0.34 | 0.23 | 0.18 | 0.15 | |
Debt to assets | 0.22 | 0.21 | 0.16 | 0.13 | 0.11 | |
Net debt to EBITDA | 0.46 | 0.79 | 0.88 | 0.15 | -0.59 | |
Current ratio | 1.39 | 1.4 | 1.57 | 1.79 | 1.88 | |
Interest coverage | 9.5 | 7.88 | 3.91 | 8.99 | 11.74 | |
Income quality | 1.5 | 39.37 | 3.5 | 2.38 | 4.4 | |
Dividend Yield | 0.03 | 0.06 | 0.01 | 0.01 | 0.02 | |
Payout ratio | 0.41 | 22.3 | 0.46 | 0.32 | 0.78 | |
Sales general and administrative to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Research and developement to revenue | 0.04 | 0.04 | 0.06 | 0.06 | 0.05 | |
Intangibles to total assets | 0.11 | 0.08 | 0.09 | 0.09 | 0.09 | |
Capex to operating cash flow | -0.16 | -0.37 | -0.17 | -0.22 | -0.14 | |
Capex to revenue | -0.02 | -0.05 | -0.02 | -0.03 | -0.02 | |
Capex to depreciation | -0.4 | -0.91 | -0.37 | -0.56 | -0.38 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 5.38 | 1.16 | 3.38 | 4.56 | 3.54 | |
ROIC | 0.07 | 0.02 | 0.03 | 0.05 | 0.05 | |
Return on tangible assets | 0.06 | 0 | 0.03 | 0.05 | 0.03 | |
Graham Net | 0 | -0.17 | 0.06 | 0.21 | 0.46 | |
Working capital | 655.57M | 594.92M | 625.03M | 791.68M | 913.67M | |
Tangible asset value | 2.46B | 2.39B | 2.46B | 2.59B | 2.65B | |
Net current asset value | 533.82M | 481.69M | 529.1M | 683.99M | 829.91M | |
Invested capital | 0.36 | 0.34 | 0.23 | 0.18 | 0.15 | |
Average receivables | 921.27M | 990.93M | 931.48M | 819.01M | 804.22M | |
Average payables | 235.55M | 218.55M | 157.18M | 152.25M | 174.52M | |
Average inventory | 532.74M | 559.25M | 529.84M | 509.51M | 485.07M | |
Days sales outstanding | 121.91 | 120.86 | 120.02 | 103.31 | 110.94 | |
Days payables outstanding | 86.43 | 53.14 | 52.76 | 51.32 | 60.13 | |
Days of inventory on hand | 174.52 | 185.01 | 171.69 | 176.55 | 136.68 | |
Receivables turnover | 2.99 | 3.02 | 3.04 | 3.53 | 3.29 | |
Payables turnover | 4.22 | 6.87 | 6.92 | 7.11 | 6.07 | |
Inventory turnover | 2.09 | 1.97 | 2.13 | 2.07 | 2.67 | |
ROE | 0.09 | 0 | 0.04 | 0.06 | 0.04 | |
Capex per share | -0.09 | -0.23 | -0.08 | -0.12 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.88 | 1 | 1.04 | 0.96 | 0.88 | |
Net income per share | 0.01 | 0 | 0.14 | 0.08 | 0.06 | |
Operating cash flow per share | 0.01 | 0 | 0.14 | 0.21 | 0.11 | |
Free cash flow per share | -0.01 | -0.03 | 0.11 | 0.17 | 0.06 | |
Cash per share | 0.76 | 0.84 | 1 | 0.87 | 0.78 | |
Book value per share | 3.86 | 3.97 | 4 | 3.99 | 4.02 | |
Tangible book value per share | 3.4 | 3.54 | 3.58 | 3.55 | 3.56 | |
Share holders equity per share | 3.86 | 3.97 | 4 | 3.99 | 4.02 | |
Interest debt per share | 0.71 | 0.6 | 0.59 | 0.47 | 0.33 | |
Market cap | 4.39B | 4.4B | 5.44B | 5.4B | 6.41B | |
Enterprise value | 4.35B | 4.17B | 5.12B | 5.09B | 6.08B | |
P/E ratio | 121.73 | -400.99 | 12.65 | 22.26 | 35.02 | |
Price to sales ratio | 6.46 | 5.9 | 6.79 | 7.37 | 9.62 | |
POCF ratio | 486.93 | -1.6K | 50.61 | 33.66 | 80.38 | |
PFCF ratio | -780.04 | -200.66 | 63.14 | 40.78 | 130.77 | |
P/B Ratio | 1.48 | 1.48 | 1.77 | 1.78 | 2.11 | |
PTB ratio | 1.48 | 1.48 | 1.77 | 1.78 | 2.11 | |
EV to sales | 6.4 | 5.59 | 6.4 | 6.95 | 9.12 | |
Enterprise value over EBITDA | 1.2K | 52.38 | 38.01 | 72.78 | 123.71 | |
EV to operating cash flow | 482.37 | -1.52K | 47.71 | 31.73 | 76.19 | |
EV to free cash flow | -772.74 | -190.3 | 59.52 | 38.44 | 123.96 | |
Earnings yield | 0 | 0 | 0.02 | 0.01 | 0.01 | |
Free cash flow yield | 0 | 0 | 0.02 | 0.02 | 0.01 | |
Debt to equity | 0.18 | 0.15 | 0.15 | 0.12 | 0.08 | |
Debt to assets | 0.13 | 0.11 | 0.11 | 0.09 | 0.06 | |
Net debt to EBITDA | -11.35 | -2.85 | -2.31 | -4.42 | -6.8 | |
Current ratio | 1.86 | 1.88 | 2.03 | 2.13 | 2.18 | |
Interest coverage | 0.31 | -1.04 | 31.78 | 14.37 | 22.63 | |
Income quality | 1 | 1 | 1 | 2.65 | 1.74 | |
Dividend Yield | 0 | 0 | 0 | 0.01 | 0 | |
Payout ratio | 0.49 | -2.33 | 0.04 | 0.71 | 0.06 | |
Sales general and administrative to revenue | 0.25 | -0.19 | 0.08 | -0.06 | 0.27 | |
Research and developement to revenue | 0.06 | 0.05 | 0.03 | 0.03 | 0.05 | |
Intangibles to total assets | 0.1 | 0.09 | 0.09 | 0.09 | 0.1 | |
Capex to operating cash flow | -1.62 | 6.99 | -0.2 | -0.17 | -0.39 | |
Capex to revenue | -0.02 | -0.03 | -0.03 | -0.04 | -0.05 | |
Capex to depreciation | -0.36 | -0.47 | -0.53 | -0.7 | 0.39 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.01 | 0.57 | 3.54 | 2.67 | 2.34 | |
ROIC | 0 | 0 | 0.03 | 0.02 | 0.01 | |
Return on tangible assets | 0 | 0 | 0.03 | 0.02 | 0.01 | |
Graham Net | 0.45 | 0.46 | 0.69 | 0.67 | 0.63 | |
Working capital | 863.31M | 913.67M | 1.04B | 992.39M | 961.5M | |
Tangible asset value | 2.62B | 2.65B | 2.75B | 2.69B | 2.7B | |
Net current asset value | 782.82M | 829.91M | 963.7M | 911.19M | 885.14M | |
Invested capital | 0.18 | 0.15 | 0.15 | 0.12 | 0.08 | |
Average receivables | 816.56M | 822.03M | 848.43M | 838.54M | 788.92M | |
Average payables | 165.05M | 179.24M | 199.65M | 197.8M | 196.74M | |
Average inventory | 460.62M | 446.62M | 433.94M | 405.71M | 399.37M | |
Days sales outstanding | 108.45 | 99.74 | 97.89 | 99.1 | 104.16 | |
Days payables outstanding | 47.88 | 53.31 | 54.89 | 53.74 | 61.22 | |
Days of inventory on hand | 132.16 | 121.19 | 113.94 | 108.86 | 124.55 | |
Receivables turnover | 0.83 | 0.9 | 0.92 | 0.91 | 0.86 | |
Payables turnover | 1.88 | 1.69 | 1.64 | 1.67 | 1.47 | |
Inventory turnover | 0.68 | 0.74 | 0.79 | 0.83 | 0.72 | |
ROE | 0 | 0 | 0.03 | 0.02 | 0.02 | |
Capex per share | -0.02 | -0.03 | -0.03 | -0.04 | -0.04 |
600351.SS Frequently Asked Questions
What is Yabao Pharmaceutical Group Co., Ltd stock symbol ?
Yabao Pharmaceutical Group Co., Ltd is a CN stock and trading under the symbol 600351.SS
What is Yabao Pharmaceutical Group Co., Ltd stock quote today ?
Yabao Pharmaceutical Group Co., Ltd stock price is $6.06 today.
Is Yabao Pharmaceutical Group Co., Ltd stock public?
Yes, Yabao Pharmaceutical Group Co., Ltd is a publicly traded company.